Astria Therapeutics Stock Buy Hold or Sell Recommendation
| ATXS Stock | USD 9.64 0.16 1.63% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Astria Therapeutics is 'Hold'. Macroaxis provides Astria Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ATXS positions. The advice algorithm takes into account all of Astria Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Astria Therapeutics' buy or sell advice are summarized below:
Real Value 13.27 | Target Price 22.43 | Hype Value 9.47 | Market Value 9.64 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Astria Therapeutics given historical horizon and risk tolerance towards Astria Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Astria Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Astria |
Execute Astria Therapeutics Buy or Sell Advice
The Astria recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Astria Therapeutics. Macroaxis does not own or have any residual interests in Astria Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Astria Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Modest | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Astria Therapeutics Trading Alerts and Improvement Suggestions
| Astria Therapeutics had very high historical volatility over the last 90 days | |
| Astria Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (72.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Astria Therapeutics currently holds about 102.48 M in cash with (68.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.87. | |
| Astria Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Astria Therapeutics Stock Price Down 2.4 percent - MarketBeat |
Astria Therapeutics Returns Distribution Density
The distribution of Astria Therapeutics' historical returns is an attempt to chart the uncertainty of Astria Therapeutics' future price movements. The chart of the probability distribution of Astria Therapeutics daily returns describes the distribution of returns around its average expected value. We use Astria Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Astria Therapeutics returns is essential to provide solid investment advice for Astria Therapeutics.
| Mean Return | 0.62 | Value At Risk | -5.81 | Potential Upside | 9.46 | Standard Deviation | 5.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Astria Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Astria Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Astria Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Astria Therapeutics backward and forwards among themselves. Astria Therapeutics' institutional investor refers to the entity that pools money to purchase Astria Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stempoint Capital Lp | 2023-12-31 | 857 K | Altium Capital Management, Lp | 2023-12-31 | 730 K | Geode Capital Management, Llc | 2023-12-31 | 697.2 K | Logos Global Management Lp | 2023-12-31 | 545 K | Tri Locum Partners Lp | 2023-12-31 | 542.9 K | State Street Corporation | 2023-12-31 | 529.7 K | Dafna Capital Management Llc | 2023-12-31 | 449 K | Driehaus Capital Management Llc | 2023-12-31 | 425.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 377.5 K | Fmr Inc | 2023-12-31 | 4.8 M | Perceptive Advisors Llc | 2023-12-31 | 4 M |
Astria Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (5.0M) | 14.7M | 61.6M | (65.9M) | 155.0M | 162.8M | |
| Free Cash Flow | (26.6M) | (32.5M) | (30.2M) | (43.6M) | (68.5M) | (65.0M) | |
| Other Non Cash Items | 33K | 58K | 164.7M | 1.1M | 545K | 517.8K | |
| Capital Expenditures | 12K | 33K | 21K | 91K | 25K | 23.8K | |
| Net Income | (26.3M) | (37.3M) | (194.9M) | (51.8M) | (72.9M) | (76.5M) | |
| End Period Cash Flow | 10.4M | 25.1M | 86.6M | 20.7M | 175.7M | 184.5M | |
| Investments | (4.1M) | 6.3M | (19M) | (167.0M) | 135.1M | 141.8M | |
| Change To Netincome | 1.6M | 1.4M | 168.1M | 4.7M | 5.4M | 5.1M |
Astria Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Astria Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Astria Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Astria stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.41 | |
β | Beta against NYSE Composite | 2.44 | |
σ | Overall volatility | 4.51 | |
Ir | Information ratio | 0.10 |
Astria Therapeutics Volatility Alert
Astria Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Astria Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Astria Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Astria Therapeutics Fundamentals Vs Peers
Comparing Astria Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Astria Therapeutics' direct or indirect competition across all of the common fundamentals between Astria Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Astria Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Astria Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Astria Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Astria Therapeutics to competition |
| Fundamentals | Astria Therapeutics | Peer Average |
| Return On Equity | -0.31 | -0.31 |
| Return On Asset | -0.17 | -0.14 |
| Current Valuation | 387.17 M | 16.62 B |
| Shares Outstanding | 54.9 M | 571.82 M |
| Shares Owned By Insiders | 0.48 % | 10.09 % |
| Shares Owned By Institutions | 88.00 % | 39.21 % |
| Number Of Shares Shorted | 5.06 M | 4.71 M |
| Price To Book | 4.02 X | 9.51 X |
| EBITDA | (67.83 M) | 3.9 B |
| Net Income | (72.89 M) | 570.98 M |
| Cash And Equivalents | 102.48 M | 2.7 B |
| Cash Per Share | 7.87 X | 5.01 X |
| Total Debt | 329 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 19.87 X | 2.16 X |
| Book Value Per Share | 3.60 X | 1.93 K |
| Cash Flow From Operations | (68.44 M) | 971.22 M |
| Short Ratio | 3.45 X | 4.00 X |
| Earnings Per Share | (2.42) X | 3.12 X |
| Target Price | 24.57 | |
| Number Of Employees | 59 | 18.84 K |
| Beta | 0.71 | -0.15 |
| Market Capitalization | 538.05 M | 19.03 B |
| Total Asset | 254.67 M | 29.47 B |
| Retained Earnings | (580.53 M) | 9.33 B |
| Working Capital | 239.39 M | 1.48 B |
| Net Asset | 254.67 M |
Note: Acquisition by Agarwal Sunil of 28200 shares of Astria Therapeutics at 11.4 subject to Rule 16b-3 [view details]
Astria Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Astria . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Astria Therapeutics Buy or Sell Advice
When is the right time to buy or sell Astria Therapeutics? Buying financial instruments such as Astria Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Cash | 86.5M | 20.5M | 175.7M | 184.5M | Accounts Payable | 1.6M | 788K | 1.5M | 1.3M |
Use Investing Ideas to Build Portfolios
In addition to having Astria Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Copper Thematic Idea Now
Copper
Companies involved in production of copper. The Copper theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Astria Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Astria Stock analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Astria Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Astria Therapeutics. If investors know Astria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Astria Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Return On Assets (0.17) | Return On Equity (0.31) |
The market value of Astria Therapeutics is measured differently than its book value, which is the value of Astria that is recorded on the company's balance sheet. Investors also form their own opinion of Astria Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Astria Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astria Therapeutics' market value can be influenced by many factors that don't directly affect Astria Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astria Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Astria Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.